Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted microRNA-sequencing for precise biomarker molecule counting

ABSTRACT: Targeted microRNA-sequencing for precise biomarker molecule counting

PROVIDER: PRJNA429135 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR6451370.fastq.gz	Fastqsanger.gz
	SRR6451371.fastq.gz	Fastqsanger.gz
	SRR6451372.fastq.gz	Fastqsanger.gz
	SRR6451373.fastq.gz	Fastqsanger.gz
	SRR6451364.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Targeted microRNA-sequencing for precise biomarker molecule counting

Project description:This study introduced a novel targeted allele counting by sequencing (TAC-seq) method to quantify miRNA molecules.

2018-03-01 | GSE108916 | GEO

TAC-seq: targeted DNA and RNA sequencing for precise biomarker molecule counting.

Project description:Targeted next-generation sequencing (NGS) methods have become essential in medical research and diagnostics. In addition to NGS sensitivity and high-throughput capacity, precise biomolecule counting based on unique molecular identifier (UMI) has potential to increase biomolecule detection accuracy. Although UMIs are widely used in basic research its introduction to clinical assays is still in progress. Here, we present a robust and cost-effective TAC-seq (Targeted Allele Counting by sequencing) method that uses UMIs to estimate the original molecule counts of mRNAs, microRNAs, and cell-free DNA. We applied TAC-seq in three different clinical applications and compared the results with standard NGS. RNA samples extracted from human endometrial biopsies were analyzed using previously described 57 mRNA-based receptivity biomarkers and 49 selected microRNAs at different expression levels. Cell-free DNA aneuploidy testing was based on cell line (47,XX, +21) genomic DNA. TAC-seq mRNA profiling showed identical clustering results to transcriptome RNA sequencing, and microRNA detection demonstrated significant reduction in amplification bias, allowing to determine minor expression changes between different samples that remained undetermined by standard NGS. The mimicking experiment for cell-free DNA fetal aneuploidy analysis showed that TAC-seq can be applied to count highly fragmented DNA, detecting significant (p = 7.6 × 10-4) excess of chromosome 21 molecules at 10% fetal fraction level. Based on three proof-of-principle applications we demonstrate that TAC-seq is an accurate and highly potential biomarker profiling method for advanced medical research and diagnostics.

| S-EPMC6299075 | biostudies-literature

targeted allele counting by sequencing (TAC-seq)

Project description:targeted allele counting by sequencing (TAC-seq)

| PRJNA432900 | ENA

Single-cell RNA sequencing with molecular spikes to determine RNA counting accuracy

Project description:Molecule counting is central to single-cell sequencing, yet no experimental strategy to evaluate counting performance exist. Here, we introduce RNA spike-ins containing inbuilt unique molecular identifiers (molecular spikes) that we use to monitor single-cell RNA counting performance across methods and to identify experimental steps essential for accurate counting. In this dataset, we add molecular spikes to popular single-cell RNA-seq protocols: SCRB-seq, Smart-seq3 and 10x Genomics (v2). For SCRB-seq and Smart-seq3, we also include variations of the library preparation procedure that are suspected to lead to changes in the UMI counting accuracy.

2022-02-16 | E-MTAB-10372 | biostudies-arrayexpress

Artificial Biomarker-based Feedback-regulated Personalized Precise Thrombolysis with Lower Hemorrhagic Risk

Project description:Artificial Biomarker-based Feedback-regulated Personalized Precise Thrombolysis with Lower Hemorrhagic Risk

| PRJNA1073837 | ENA

Artificial Biomarker-based Feedback-regulated Personalized Precise Thrombolysis with Lower Hemorrhagic Risk

Project description:Intravenous thrombolysis possesses critical defects in efficiency and post-thrombolysis hemorrhage due to the current empirical body weight-based medication strategy. However, the inherent heterogeneity of thrombi, instead of body weight, endows thrombi different thrombolysis resistance and affect the thrombolytic outcome. The lack of methods for perceiving thrombolysis resistance has severely hindered the precise medication of vascular embolization. Here, we described the relationship between the thrombin heterogeneity in thrombi and the thrombolysis resistance of thrombi, and created an artificial biomarker-based nano-patrol system to perceive and report the thrombolysis resistance of thrombi taking advantage of the specific recognition and allosteric ability of aptamer-based DNA structure. The nano-patrols are able to accomplish thrombolysis resistance-matched personalized precise therapy through the NIR-Ⅱ laser-regulated synergistic thrombolytic effect, according to the feedback signal from artificial biomarkers. This new strategy depicted enhanced thrombolytic efficiency than alteplase for rats, mini pigs and clinical thrombi, achieved recanalization in thrombotic model where alteplase encountered failure. Moreover, the nano-patrol system remarkably reduced the infarct volume and the hemorrhagic transformation risk (0.12-fold of alteplase) of cerebral thrombosis. This nano-patrol system developed new tool for the assessment of thrombolysis resistance and personalized precise thrombolysis with lower hemorrhagic risk.

2025-01-22 | GSE255147 | GEO

Counting abortive transcription by Flux-seq

Project description:Counting abortive transcription by Flux-seq

| PRJNA854354 | ENA

Direct detection of circulating microRNA-122 using dynamic chemical labelling with single molecule detection overcomes stability and isomiR challenges for biomarker qualification

Project description:Circulating microRNAs are biomarkers reported to be stable and translational acrossspecies. miR-122 (miR-122-5p) is a hepatocyte-specific microRNA biomarker for drug-induced liver injury (DILI). Our objective was to develop an extraction-free andamplification-free detection method for measuring miR-122 that has translationalutility in context of DILI. We developed a single molecule dynamic chemical labelling(DCL) assay based on miR-122 hybridization to an abasic peptide nucleic acid probethat contained a reactive amine instead of a nucleotide at a specific position in thesequence. The single molecule DCL assay specifically measured miR-122 directly from10 μL of serum or plasma without any extraction steps, with a fit-for-purpose limit ofdetection of 1.32 pM. In 192 human serum samples, DCL accurately identified patientsat risk of DILI (area under ROC curve 0.98 (95%CI 0.96-1), P<0.0001). The miR-122assay also quantified liver injury in rats and dogs. When DCL beads were added toserum, the miR-122 signal was stabilised (no loss of signal after 14 days at roomtemperature). By contrast, there was substantial degradation of miR-122 in the absenceof beads (≈60% lost in 1 day). RNA sequencing demonstrated the presence of multiplemiR-122 isomiRs with DILI that were at low concentration or not present in healthypatient serum. Sample degradation over time produced more isomiRs, particularlyrapidly with DILI. PCR was inaccurate when analysing miR-122 isomiRs, whereas theDCL assay demonstrated accurate quantification. In summary, the DCL assay canaccurately measure miR-122 directly from serum and plasma to diagnose liver injury inhumans and other species, and can overcome important microRNA biomarker analyticaland biological challenges.

2019-11-23 | GSE140833 | GEO

Precise small molecule cleavage of a r(CUG) repeat expansion in a myotonic dystrophy mouse model

Project description:Precise small molecule cleavage of a r(CUG) repeat expansion in a myotonic dystrophy mouse model

| PRJNA525438 | ENA

Digital counting of nucleic acid molecules using random base molecular barcodes

Project description:Several template DNA molecules with random base molecular barcodes were amplified and sequenced, and the efficacy of the random base barcode for digital counting was shown.

2017-10-19 | GSE94895 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data